Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Express Scripts
Merck
US Department of Justice
Colorcon

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,875,630

« Back to Dashboard

Which drugs does patent 7,875,630 protect, and when does it expire?

Patent 7,875,630 protects ALTABAX and is included in one NDA.

This patent has thirteen patent family members in six countries.

Summary for Patent: 7,875,630
Title:Process salts compositions and use
Abstract:The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.
Inventor(s): Breen; Gary Francis (Tonbridge, GB), Forth; Michael Anthony (Tonbridge, GB), Kopelman; Susan ShuMei Hu (King of Prussia, PA), Muller; Francis Xavier (King of Prussia, PA), Sanderson; Francis Dominic (Harlow, GB)
Assignee: Glaxo Group Limited (Greenford Middlesex, unknown)
Application Number:10/570,410
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,875,630
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 7,875,630

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aqua Pharms Llc ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,875,630

PCT Information
PCT FiledAugust 30, 2004PCT Application Number:PCT/US2004/028159
PCT Publication Date:March 17, 2005PCT Publication Number: WO2005/023257

International Family Members for US Patent 7,875,630

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 450535 ➤ Sign Up
Germany 602004024417 ➤ Sign Up
European Patent Office 1663220 ➤ Sign Up
European Patent Office 2181995 ➤ Sign Up
Spain 2335284 ➤ Sign Up
Japan 2007504231 ➤ Sign Up
Japan 2012020998 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Cantor Fitzgerald
Julphar
Queensland Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.